Meta-analysis · people
Cerebrolysin beat placebo on global change in Alzheimer's at 6 months
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In pooled placebo-controlled trials, Cerebrolysin improved overall clinical ratings in mild-to-moderate Alzheimer's with safety similar to placebo, though its effect on cognition alone was clear only at 4 weeks.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2015
- Journal
- Dement Geriatr Cogn Disord
What they tested
The team set out to measure the benefits and risks of Cerebrolysin in people with mild-to-moderate Alzheimer's disease by pooling all randomized, double-blind, placebo-controlled trials, while avoiding flaws of an earlier meta-analysis.
How the study was done
A meta-analysis, which pools results from several studies, of 6 randomized, double-blind trials that compared Cerebrolysin at 30 ml/day with placebo (a dummy treatment) in people with mild-to-moderate Alzheimer's disease. The pooled data covered results at 4 weeks and 6 months, and drew on individual patient data, published group results or both.

What they found
Cerebrolysin did better than placebo on cognitive function at 4 weeks (standardized mean difference -0.40; 95% CI -0.66 to -0.13), but the gap at 6 months (-0.37; 95% CI -0.90 to 0.16) was not statistically significant. On global clinical change, an overall rating of how a patient was doing, the odds of improving favored Cerebrolysin at both 4 weeks (odds ratio 3.32) and 6 months (odds ratio 4.98). A combined measure of global change plus cognition also favored Cerebrolysin at both time points (Mann-Whitney 0.57 each time). Side effects and other safety measures were similar to placebo.
What it doesn’t show
The pooled results cover two time points, 4 weeks and 6 months, and mix individual patient data with published group results across 6 trials. The cognitive benefit seen at 4 weeks was not statistically significant at 6 months.
The paper
Gauthier et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015.
The compound
More studies on Cerebrolysin
- Cerebrolysin: better NIHSS scores after stroke across nine trialsMeta-analysis · people · 2018
- Cerebrolysin: better arm function at day 90 after stroke in CARSRandomized trial · people · 2016
- Cerebrolysin: no overall benefit in acute ischemic stroke at 90 daysRandomized trial · people · 2012
- Every study on Cerebrolysin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.